The Tianjin, China-based company, which was the first to move a vaccine into Phase II development, also became the first to published peer-reviewed data, from its Phase I study. Moderna released preliminary data this week, but it was seen as too early for interpreting its vaccine’s efficacy.

LEAVE A REPLY

Please enter your comment!
Please enter your name here